237 related articles for article (PubMed ID: 22624727)
1. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo.
Ackler S; Mitten MJ; Chen J; Clarin J; Foster K; Jin S; Phillips DC; Schlessinger S; Wang B; Leverson JD; Boghaert ER
Br J Pharmacol; 2012 Oct; 167(4):881-91. PubMed ID: 22624727
[TBL] [Abstract][Full Text] [Related]
2. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo.
Ackler S; Mitten MJ; Foster K; Oleksijew A; Refici M; Tahir SK; Xiao Y; Tse C; Frost DJ; Fesik SW; Rosenberg SH; Elmore SW; Shoemaker AR
Cancer Chemother Pharmacol; 2010 Oct; 66(5):869-80. PubMed ID: 20099064
[TBL] [Abstract][Full Text] [Related]
3. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
[TBL] [Abstract][Full Text] [Related]
4. Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives.
Rummel MJ; Mitrou PS; Hoelzer D
Semin Oncol; 2002 Aug; 29(4 Suppl 13):27-32. PubMed ID: 12170430
[TBL] [Abstract][Full Text] [Related]
5. Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management.
Brugger W; Ghielmini M
Oncologist; 2013; 18(8):954-64. PubMed ID: 23900001
[TBL] [Abstract][Full Text] [Related]
6. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.
Mondello P; Steiner N; Willenbacher W; Wasle I; Zaja F; Zambello R; Visentin A; Mauro E; Ferrero S; Ghione P; Pitini V; Cuzzocrea S; Mian M
Ann Hematol; 2016 Jun; 95(7):1107-14. PubMed ID: 27103007
[TBL] [Abstract][Full Text] [Related]
7. Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma.
Kaneko N; Mitsuoka K; Amino N; Yamanaka K; Kita A; Mori M; Miyoshi S; Kuromitsu S
Clin Cancer Res; 2014 Apr; 20(7):1814-22. PubMed ID: 24486595
[TBL] [Abstract][Full Text] [Related]
8. Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Garnock-Jones KP
Drugs; 2010 Sep; 70(13):1703-18. PubMed ID: 20731477
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of the potential for drug-drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
Darwish M; Burke JM; Hellriegel E; Robertson P; Phillips L; Ludwig E; Munteanu MC; Bond M
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1119-27. PubMed ID: 24677018
[TBL] [Abstract][Full Text] [Related]
10. In vitro studies with bendamustine: enhanced activity in combination with rituximab.
Rummel MJ; Chow KU; Hoelzer D; Mitrou PS; Weidmann E
Semin Oncol; 2002 Aug; 29(4 Suppl 13):12-4. PubMed ID: 12170426
[TBL] [Abstract][Full Text] [Related]
11. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
Flinn IW; van der Jagt R; Kahl B; Wood P; Hawkins T; MacDonald D; Simpson D; Kolibaba K; Issa S; Chang J; Trotman J; Hallman D; Chen L; Burke JM
J Clin Oncol; 2019 Apr; 37(12):984-991. PubMed ID: 30811293
[TBL] [Abstract][Full Text] [Related]
12. Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales.
Dewilde S; Woods B; Castaigne JG; Parker C; Dunlop W
J Med Econ; 2014 Feb; 17(2):111-24. PubMed ID: 24308372
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies.
Roberts AW; Advani RH; Kahl BS; Persky D; Sweetenham JW; Carney DA; Yang J; Busman TB; Enschede SH; Humerickhouse RA; Seymour JF
Br J Haematol; 2015 Sep; 170(5):669-78. PubMed ID: 25942994
[TBL] [Abstract][Full Text] [Related]
14. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Ogura M; Ando K; Taniwaki M; Watanabe T; Uchida T; Ohmachi K; Matsumoto Y; Tobinai K;
Cancer Sci; 2011 Sep; 102(9):1687-92. PubMed ID: 21624007
[TBL] [Abstract][Full Text] [Related]
15. Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab.
García Muñoz R; Izquierdo-Gil A; Muñoz A; Roldan-Galiacho V; Rabasa P; Panizo C
Ann Hematol; 2014 Nov; 93(11):1879-87. PubMed ID: 24951124
[TBL] [Abstract][Full Text] [Related]
16. Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.
Mahadevan D; Stejskal A; Cooke LS; Manziello A; Morales C; Persky DO; Fisher RI; Miller TP; Qi W
Clin Cancer Res; 2012 Apr; 18(8):2210-9. PubMed ID: 22374334
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of Bendamustine-Rituximab Compared to R-CHOP/R-CVP as a First-Line Treatment of Indolent Non-Hodgkin's Lymphoma or Mantle-Cell Lymphoma.
Edina BC; Rinaldi I
Acta Med Indones; 2022 Apr; 54(2):316-323. PubMed ID: 35818660
[TBL] [Abstract][Full Text] [Related]
18. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
[TBL] [Abstract][Full Text] [Related]
19. Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma.
Hoy SM
Drugs; 2012 Oct; 72(14):1929-50. PubMed ID: 22950536
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with ofatumumab and bendamustine in xenograft model of chronic lymphocytic leukaemia.
Haskova Z; Whitacre MN; Dede KA; Lee JM; Trulli SH; Ciucci M; Toso JF; White JR; Jonak ZL
Br J Haematol; 2012 Feb; 156(3):402-4. PubMed ID: 21848524
[No Abstract] [Full Text] [Related]
[Next] [New Search]
